WHO Pharmaceuticals Newsletter 2003, No. 04
(2003; 13 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoREGULATORY MATTERS
Cerrar esta carpetaSAFETY OF MEDICINES
Ver el documentoATYPICAL ANTI-PSYCHOTICS - Reports of hypertension
Ver el documentoBOTULINUM A - Patients misled over safety
Ver el documentoCHELIDONIUM MAJUS - Statement to advise use under supervision
Ver el documentoCYCLO-OXYGENASE (COX)-2 INHIBITORS - Reports of hepatotoxicity
Ver el documentoETONOGESTREL - Vaginal bleeding with sub-dermal implant
Ver el documentoFLUTICASONE - ADR update
Ver el documentoGATIFLOXACIN - Reports of abnormal glucose metabolism
Ver el documentoHORMONE REPLACEMENT THERAPY (HRT) - ‘Million Women Study’ confirms breast cancer association
Ver el documentoMEDROXY-PROGESTERONE - Reports of contraception failure with depot preparations
Ver el documentoMEFLOQUINE - Patient guide warns of psychiatric adverse events
Ver el documentoMETHOTREXATE - New solutions to prevent fatalities/adverse events
Ver el documentoMINOCYCLINE - Hepatic reactions
Ver el documentoPIPERACILLIN - Serum methotrexate monitoring advised during concomitant therapy
Ver el documentoRIFAMPICIN & PYRAZINAMIDE - Warning against use in latent tuberculosis
Ver el documentoSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs): Reports of hyponatraemia
Ver el documentoSIBUTRAMINE - Serotonin syndrome
Ver el documentoTICLOPIDINE - No decrease in ADR reports
Ver el documentoVIGA/VIGA FOR WOMEN - Presence of sildenafil
Ver el documentoWARFARIN & MICONAZOLE - Reminder about interaction
Abrir esta carpeta y ver su contenidoDRUGS IN THE NEWS
 

SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs): Reports of hyponatraemia

Australia. The Adverse Drug Reactions Advisory Committee (ADRAC) has now received a total of 311 reports of hyponatraemia associated with the use of SSRIs and venlafaxine; in 67 of these reports the patient also had the syndrome of inappropriate antidiuretic hormone secretion. An SSRI was the only suspected drug in more than two-thirds of the 311 reports, although a small proportion (14%) of cases involved the concurrent use of a diuretic. The majority (75%) of patients were women and most (85%) were older than 60 years (mean age 77 years). Hyponatraemia usually occurred within the first 30 days of use and in many cases was the only abnormality reported, with a median serum sodium nadir of 120 mmol/L (range 113-133). Approximately two-thirds of cases recovered fully after withdrawal of the SSRI and fluid restriction, but three cases had a fatal outcome.

Reports in WHO-file: SSRIs: Hyponatraemia 2381

Reference:

Adverse Drug Reactions Advisory Committee (ADRAC).
Hyponatraemia with SSRIs. Australian Adverse Drug Reactions Bulletin 22: 10, Jun 2003.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013